Evidence map›Paper›PMID 38983163›Full record

ArticleJournal of thoracic disease2024

Siwei Xu, Yujian Xu, Wenjun Chai, Xiaoli Liu, Jing Li, Lei Sun, Hongyu Pan, Mingxia Yan

Erratum issuedAbstract read
In one paragraph

Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Erratum:Journal of thoracic disease · 2025
    Article
  4. Translational lung cancer research · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Siwei Xu *Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Yujian Xu *Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenjun ChaiCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoli LiuCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Jing LiCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Lei SunCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongyu PanCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Mingxia YanCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is the most common primary malignant tumor of the lung, and as one of the malignant tumors that pose the greatest threat to the health of the population, the incidence rate has remained high in recent years. Previous studies have shown that Methods: We assessed the expression levels of Results: Conclusions: The evidence revealed a correlation between

Indexed as

immune infiltrationKLRB1Lung adenocarcinoma (LUAD)MAPK/ERK signaling pathwayprognostic implications

Identifiers

PMID38983163
PMCPMC11228747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.